Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1236-1247
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1236
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1236
Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma
Kun-Peng Ma, Jin-Xin Fu, Feng Duan, Mao-Qiang Wang, Department of Interventional Radiology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing 100853, China
Kun-Peng Ma, Chinese People's Liberation Army Medical School, Beijing 100853, China
Author contributions: Wang MQ contributed to the conception and design; Ma KP and Fu JX contributed to the analysis and interpretation of data; Ma KP and Duan F contributed to the writing, review, and/or revision of the manuscript; All authors contributed to the acquisition of data (acquired and managed patients) and final approved the manuscript.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of the Chinese People's Liberation Army General Hospital.
Informed consent statement: As the study used anonymous and pre-existing data, the requirement for the informed consent from patients was waived.
Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose.
Data sharing statement: The authors declare that all data and materials supporting the findings of this study are available within the article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mao-Qiang Wang, MD, PhD, Deputy Director, Department of Interventional Radiology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, No. 28 Fuxin Road, Haidian District, Beijing 100853, China. wangmaoqiang301@163.com
Received: October 4, 2023
Peer-review started: October 4, 2023
First decision: December 18, 2023
Revised: December 29, 2023
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: April 15, 2024
Peer-review started: October 4, 2023
First decision: December 18, 2023
Revised: December 29, 2023
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: April 15, 2024
Core Tip
Core Tip: Transarterial chemoembolization/lenvatinib/programmed cell death protein-1 combined treatment was well tolerated with encouraging efficacy in unresectable hepatocellular carcinoma patients. The patients with Barcelona Clinic Liver Cancer Classification (BCLC) B, with early neutrophil-to-lymphocyte ratio (NLR) response (decrease) and early alpha fetoprotein (AFP) response (decrease > 20%) might achieve better clinical outcomes with this triple therapy. It is advisable that BCLC stage, NLR, and AFP should be considered at clinical decision-making in order to obtain better prognosis.